share_log

博雅生物(300294.SZ):2023年公司Ⅷ因子、PCC销售态势良好,整体销量增长迅速

Liberal Arts Biotech (300294.SZ): In 2023, the company's VIII factor and PCC sales trends were good, and overall sales grew rapidly

Gelonghui Finance ·  Apr 2 03:17

Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by a specific target on April 1, 2024. Regarding “the sales situation of the company's factor VIII, PCC and other products,” the company replied that in 2023, the company's sales trend of Factor VIII and PCC was good, and overall sales were growing rapidly. According to hospital CPA sample statistics, the company's prothrombin complex (PCC) ranks third in the industry. The company attaches importance to building an academic system and continuously improving product coverage and penetration rate.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment